Abivax (AAVXF) Other Accumulated Expenses (2024 - 2026)

Abivax has reported Other Accumulated Expenses for 3 years, with the latest figure at $71.5 million in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 117348.62% year-over-year to $71.5 million in Q1 2026; TTM through Mar 2026 was $71.5 million, a 117348.62% increase from a year earlier, with the FY2025 full-year figure at $71.8 million, up 36.89% from the prior year.
• Other Accumulated Expenses was $71.5 million for Q1 2026 at Abivax, roughly flat from $71.8 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $71.8 million in Q4 2025, with the low at -$80170.0 in Q3 2024.
• Average Other Accumulated Expenses over 3 years is $32.6 million, with a median of $26.2 million recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Other Accumulated Expenses jumped 36.89% in 2025, then surged 117348.62% in 2026.
• Over 3 years, Other Accumulated Expenses stood at $52.5 million in 2024, then soared by 36.89% to $71.8 million in 2025, then dropped by 0.4% to $71.5 million in 2026.
• The last three Other Accumulated Expenses figures came in at $71.5 million (Q1 2026), $71.8 million (Q4 2025), and -$61009.3 (Q1 2025), per Business Quant data.